Business
Haemonetics Acquires Vivasure Medical Limited
Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative solutions designed to improve patient outcomes, today announced the acquisition of Vivasure Medical Limited (Vivasure), a Galway, Ireland-based company pioneering next-generation technology for percutaneous vessel closure.
About this update from Haemonetics Corporation
[{"type":"text","content":"BOSTON, Jan. 9, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative solutions designed to improve patient outcomes, today announced the acquisition of Vivasure Medical Limited (Vivasure), a Galway, Ireland-based company pioneering next-generation technology for percutaneous vessel closure.","length":365,"tagName":"p"},{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":93,"url":"https://media.zenfs.com/en/prnewswire.com/512e211fe9b209e3384f3b709e0c679c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/71X37BgY0jmNJY88zYaDkg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTE2NDtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/512e211fe9b209e3384f3b709e0c679c","width":400,"height":93}},"href":"https://mma.prnewswire.com/media/351568/Haemonetics_Corporation_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Vivasure's PerQseal® Elite system uses a proprietary bioabsorbable patch to seal large-bore (up to 26 F) arteriotomies and venotomies from inside the vessel, offering a sutureless, fully absorbable solution for structural heart and endovascular procedures. In 2025, Vivasure submitted a Premarket Approval application to the U.S. FDA for the PerQseal Elite arterial closure system and received CE Mark approval in Europe for both arterial and venous indications. Results from the prospective, single-arm, multi-center ELITE arterial study demonstrated ease of use with no need for pre-close, with 0% major complications at thirty-day follow-up, and immediate median time to hemostasis1.","length":690,"tagName":"p"},{"type":"text","content":"The acquisition includes an upfront cash payment of €100 million, or approximately €52 million net of the value of certain previous investments and other loans made by Haemonetics to Vivasure as well as other customary closing adjustments, and up to an additional €85 million in contingent consideration based on sales growth and the achievement of certain other milestones, also subject to adjustment based on the value of certain prior investments and loan amounts. Haemonetics financed this transaction through available cash on hand.","length":552,"tagName":"p"},{"type":"text","content":"&quo...